Akouos, Inc.
Akouos, Inc. (AKUS): 3 pipeline candidates · ~24 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
23.9 months
D/E 0.25 · 0% dilution
Lead: Preclinical
3 candidates
N/A
N/A
A transparent, data-derived signal for Akouos, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$77.9M
Quarterly Burn
$21.1M
Runway
23.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| ak-antivegf | Preclinical |
| ak-clrn1 | Preclinical |
| ak-otof | Preclinical |
Frequently asked questions
How many drug candidates are in Akouos, Inc.'s pipeline?
Akouos, Inc. (AKUS) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Akouos, Inc.'s lead drug candidate?
Akouos, Inc.'s most advanced tracked candidate is ak-antivegf (Preclinical) for Vestibular schwannoma.
What is Akouos, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Akouos, Inc. has approximately 23.9 months of cash runway.
Who is the CEO of Akouos, Inc.?
Homology Medicines is the chief executive officer of Akouos, Inc. (AKUS).
Get the full picture on Akouos, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.